Roivant Sciences is exploding higher today following the release of positive topline results from the Phase 2 PHocus clinical trial of mosliciguat, an experimental drug developed by its subsidiary Pulmovant for patients with pulmonary hypertension associated with interstitial lung disease. The company announced these successful study outcomes late on September 7 and early on September 8, confirming that the drug met its primary goals. Alongside these results, Roivant also unveiled plans for an ongoing Phase 3 PHrontier study, further fueling investor optimism regarding the asset's clinical progression.